Piotr S.
- Country
- Poland
- Department
- Oddział Onkologii
Research Overview
- Phase 1/2 Study of EIK1005 Monotherapy and EIK1005 Plus Pembrolizumab in Patients With Advanced Solid Tumors
- Phase 3 Randomized Open-Label Study of Lorlatinib Versus Crizotinib in First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer
- Phase 3 Randomized Open-label Trial of Datopotamab Deruxtecan Plus Pembrolizumab Versus Pembrolizumab in Advanced or Metastatic PD-L1 High NSCLC
Data & Insights
Has run more than one trial at 45 of 169 partner sites.
Specializations
Lung Cancer Expertise
The investigator specializes in treating non-small cell lung cancer (NSCLC), with particular focus on advanced and metastatic cases. Their research encompasses both early-stage disease management following surgery and the treatment of ALK-positive NSCLC.
- Post-surgical therapeutic approaches
- Advanced disease management
- Targeted therapies for genetic mutations
Solid Tumor Research
The investigator conducts studies on various advanced solid tumors, including specific focus on endometrial carcinoma, urothelial carcinoma, and triple-negative breast cancer.
- Head and neck cancers
- Cervical cancer treatment
- Novel therapeutic combinations
Molecular Targeting
Their expertise extends to tumors with specific genetic alterations, including ROS1, NTRK1-3 rearrangements, and various molecular pathways involved in cancer progression.
- Targeted therapy development
- Biomarker-driven treatment
- Resistance mechanism studies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.